



Europass Curriculum Vitae

Personal information

First name / Surname DIMA DELIA MONICA

Address 16 no, Titulescu avenue, 400420, Cluj-Napoca, Romania

Telephone 0040722696791

E-mail deli_dima@yahoo.com

Nationality Romanian

Date of birth December 3rd, 1976

Gender Female

Applying for the position – 2024-2028 Senior physician responsible for TASK 8.2.6 "PROF. DR. ION CHIRICUTA" Institute of Oncology Cluj-Napoca

Current position 2013 – present : **Attending Physician** – “Ion Chiricuta” Institute of Oncology, Department of Hematology, Cluj Napoca, Romania.

Occupation or position held previously to the current ones

2001: **Erasmus scholarship** at CHU Amiens, France, at the Dermatology dept, Prof Dr Denoux,

2002-2006: **hematology intern**, « Ion Chiricuta » Institute of Oncology, Hematology dept

Feb- APR 2003: **Romanian government scholarship**, at the Hematology dept, Prof DR Bernard Desablens, CHU Amiens, France

Oct- Dec 2004: **French government scholarship** through **Association Pont Neuf Paris**, at the Hematology dept, CHU Poitiers, Prof Dr Guilhot

Nov 2006: **PhD student**, Prof Dr Petrov

2016: Doctor in medicine

Mar 2007: **hematology specialist exam**, granted with a score of 9,34/10

Jun 2016 : senior hematology physician

Education and training

1995-2001: “ Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca : **MD diploma**

Nov 2006 : scholarship for PhD studies

Mar 2007 : Hematology specialist exam, granted with a score of 9,34/ 10

Areas of Interest in Translational and Clinical Medicine

- Hematologic malignancies
- Stem Cell Transplantation
- Cancers of unknown primary site
- Rare cancers

Member of Medical Research Societies

2009 – present : European Hematology Association
2002 – present : Romanian Society for Hematology

International Professional Qualification Courses and Workshops

1. Britain- Romanian Reunion on acute and chronic pain therapy, (Cluj-Napoca, Romania, September 26-28, 2003)
2. EHA-ESH-EBMT:« Communication skills- enhancing communication within the patient-doctor relationship” (Apr 3-5, 2004)
3. ESO Advanced Course of Malignant Lymphoma (Ascona, Switzerland, June 4-6, 2005)
4. ESO advanced course on malignant lymphomas (Ascona, Switzerland, April 29- May 1st, 2006)
5. ESH-EBMT training course on bone marrow transplantation (Warsow, Poland, May 24-26, 2006)
6. Intensive course on bone marrow transplantation for malignant hematologic diseases (Tg Mures, Romania, Jan 31st- Feb 3rd, 2008)
7. Intensive course on stem cell transplantation for acute and chronic myeloid leukemias (Tg Mures, Romania, Jan 29- Feb 3rd, 2009)
8. French- Romanian workshop (Cluj-Napoca, Romania, Oct 2013)
9. French-Romanian Workshop (Cluj-Napoca, Romania, Oct 2014)

Awards

Research grants coordinated:

1. Romania – European Economic Space (EES) International Research Grant Competition, November 2013 – “**Nanotechnology approach in Acute Myeloid Leukemia management**” – NanoLAM.

Other languages
Self assessment
European level
English
French

Understanding				Speaking				W	
Listening		Reading		Spoken interaction		Spoken production			
	advanced		advanced		advanced		advanced		
	advanced		medium		Advanced		medium		

Active Participant, with oral communications or poster presentations:

National Scientific Events: 30 congresses
International Scientific Events: 2010- Barcelona, Spain, 2009- Berlin, Germany, 2005- Paris, France.

Driver's licence

Yes. B driving licence

Research projects:

- a. Funding mechanism: Grant received after the FDI competition of the National Council for the Financing of University Education 2017, Project PN-III-P1-1.1-MC-2017-0449: Position: Principal investigator- Ion Chiricuta Oncology Institute. **The project supports the mobility of young investigators. My goal was to learn the laser microdissection of CON, followed by sequencing in order to identify new target miRNA for cancers of unknown origin.**
- b. Funding mechanism: Grant received after the FDI competition of the National Council for the Financing of University Education 2018, Project Project PN-III-P1-1.1-MC-2018- 1404: Position: Principal investigator – Ion Chiricuta Oncology Institute. **This project supported the mobility to World Cancer Congress, the most important oncology meeting in the world, where we presented the results of next generation sequencing in primary bone lymphomas.**
- c. Funding mechanism: Invited Professor 2019 Grant PN-III-P1-1.1-MCD-2019-0048– Gabriel Ghiaur, Johns Hopkins University School of Medicine, from the National Research Ministry, Postion: Grant director, for the Ion Chiricuta Oncology Institute. **This project supports the mobility of Professor Gabriel Ghiaur, affiliated with the Johns Hopkins University, to come to Cluj Napoca and teach state-of-the-art protocols in leukemia diagnosis and therapy.**
- d. Postdoctoral researcher candidate for: Creating a Research Group of Excellence to develop cell and immune therapy technology to target the tumor microenvironment

Publications:

Books / Book chapters:

1. LIMFOMUL HODGKIN. Anca Vasilache, **Delia Dima**. In “PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE”. Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.
2. SPLENECTOMIA. **Delia Dima**. In “PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE”. Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.
3. NEUTROPENII FEBRILE. **Delia Dima**. In “PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE”. Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.
4. PROTOCOL URGENTE HEMATOLOGICE. **Delia Dima**. In “PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE”. Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.
5. CORELATII CLINICO- GENETICO- MOLECULARE IN ONCO-HEMATOLOGIE. Ciprian Tomuleasa, **Delia Dima**. In “PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE”. Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.
6. STANDARD OF CARE IN ACUTE MYELOID LEUKEMIA. Ciprian Tomuleasa, **Delia Dima**, Ana Maria Rosu, Ioana Frinc, Ovidiu Ursa, Mariana Patiu, Andrei Cucuianu. In “Nanopharmacology in

- leukemia chemotherapy”. Andrei Cucuianu. Eikon Publishing House and Scoala Ardeleana Publishing House, Cluj-Napoca, 2015.
7. NANOPHARMACOLOGY FOR ACUTE MYELOID LEUKEMIA. Bobe Petrushev, Ioana Frinc, **Delia Dima**, Cristian Berce, Sanda Boca, Timea Simon, Sonia Selicean, Grigore Gafencu, Monica Mihaela Marta, Mihnea Zdrengea, Adrian Florea, Simion Astilean, Ioana Berindan-Neagoe, Anca Bojan, Andrei Cucuianu, Ciprian Tomuleasa. In “Nanopharmacology in leukemia chemotherapy”. Andrei Cucuianu.
 8. NANOPHARMACOLOGY IN CHRONIC LYMPHOCYTIC LEUKEMIA. Ioana Frinc, **Delia Dima**, Cristian Berce, Sanda Boca, Bobe Petrushev, Timea Simon, Sonia Selicean, Grigore Gafencu, Anca Buzoianu, Adrian Florea, Simion Astilean, Ioana Berindan-Neagoe, Oana Muresan, Ovidiu Ursa, Anca Bojan, Ciprian Tomuleasa, Andrei Cucuianu. In “Nanopharmacology in leukemia chemotherapy”. Andrei Cucuianu. Eikon Publishing House and Scoala Ardeleana Publishing House, Cluj-Napoca, 2015.
 9. MOLECULAR BIOLOGY IN AML AND CLL. Valentina Pileczki, Laura Pop, Monica Mihaela Marta, **Delia Dima**, Ioana Berindan-Neagoe. In “Nanopharmacology in leukemia chemotherapy”. Andrei Cucuianu. Eikon Publishing House and Scoala Ardeleana Publishing House, Cluj-Napoca, 2015.
 10. FUTURE DIRECTIONS IN NANOPHARMACOLOGY AND HEMATOLOGY. Cristian Berce, Ciprian Tomuleasa, Monica Mihaela Marta, Anca Bojan, **Delia Dima**, Alexandru Irimie, Andrei Cucuianu. In “Nanopharmacology in leukemia chemotherapy”. Andrei Cucuianu. Eikon Publishing House and Scoala Ardeleana Publishing House, Cluj-Napoca, 2015.
 11. Prognostic role of molecular biology and cytogenetics in autologous hematopoietic stem cell transplantation. Ciprian Tomuleasa, **Delia Dima**, Alina Tanase. In Autotransplantul de celule stem hematopoetice in hemopatiile maligne. TehnoMedia. Bucuresti 2015.
 12. **Delia Dima**. New approaches to the management of primary and secondary CNS tumors. **Chapter 8, 20 pages 167-186**. Intech. Rijeka. Croatia
 13. Coauthor to: Neoplasmele mieloproliferative – 124 pages. ISBN 978-606-17-1135-1. Casa Cartii de Stiinta. Cluj-Napoca. 2017.
 14. **Delia Dima**. Tirozinkinase- associated cardiovascular events in malignant hematological diseases. Chapter 10.2, pages 311-327, in Manual de cardio-oncologie. Editura Medicala Universitara “Iuliu Hatieganu” Cluj-Napoca. ISBN 978-973-693-990-7
 15. Ciprian Tomuleasa, Sergiu Pasca, Anca Bojan, **Delia Dima**. Cardiac evaluation for stem cell transplantation. Chapter 13, pages 353-363, in Manual de cardio-oncologie. Editura Medicala Universitara “Iuliu Hatieganu” Cluj-Napoca. ISBN 978-973-693-990-7

In extenso publications:

Papers in National Scientific Journals:

1. Cucuianu A, Stoia M, Farcas A, **Dima D**, Zdrengea M, Patiu M, Olinic D, Petrov L. Arterial stenosis and atherothrombotic events in Polycythemia Vera and Essential Thrombocythemia. Rom J Intern Med 2006; 44 (4): 397-406
2. Cucuianu A, Bacarea A, Patiu M, **Dima D**. Epigenetic changes in myelodysplastic syndrome and acute myeloid leukemia: novel targets for therapy. Rev Rom de Med de Lab 2008;11(2):39-45
3. **Dima D**, Cucuianu A, Petrov L. Cytogenetic and molecular response after dasatinib in blastic phase chronic myeloid leukemia. Case report. Journal of radiotherapy and medical oncology 2008;14(2):126-128
4. **Dima D**, Trifa AP, Cucuianu A, Popp RA, Patiu M, Petrov L. Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR. Rev Rom de Med de Lab 2008;13(4):17-20
5. **Dima D**, Cucuianu A, Arghirescu S, Dohner H. Acute Myeloid Leukemia and Type 2 Diabetes Mellitus in Complete Remission After Allogeneic Stem Cell Transplantation. Journal of radiotherapy and medical oncology 2009;15(4):245-248
6. Cucuianu A, Fetica B, **Dima D**, Coldea C. Complex immuno-chemo-antiviral therapy in Hepatitis C virus related NonHodgkin's Lymphoma: A case report and review of the literature. Journ of radiotherapy and medical oncology. Vol 16 (4): 206-112, 2010.
7. **Dima D**, Frinc CI, Patiu M, Cucuianu A. Long term remission after treatment with rituximab in a case of thrombotic thrombocytopenic purpura. RRML (4), dec 2012
8. Seliceanu EC, Patiu M, Cucuianu A, **Dima D**, Dobreanu M. Correlation of cytomorphology with flowcytometric immunophenotyping in acute myeloid leukemia. RRML, vol 21 (3/4): 333-, sep 2013.

Original Papers in International Scientific Indexed Journals:

1. Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru MS, **Dima D**, Pop IV, Popp RA. The G allele of JAK2rs10974944 SNP, part of JAK246/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. Ann Hematol, 2010 oct; 89(10):979-83 **IF 2.688**
2. Trifa AP, Popp RA, Cucuianu A, Coadă CA, Urian LG, Militaru MS, Banescu C, **Dima D**, Farcas MF, Crisan TO, Petrov L, Gug C, Pop VI. Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms. Leukemia and Lymphoma. Feb 2012

3. AP. Trifa, A. Cucuianu, R. A. Popp, R. M. Costache, C. A. Coadă, A. D. Sarca, L. G. Urian, **D. Dima**, L. Petrov, M. F. Farcas, M. S. Militaru, I. V. Pop. Analysis of the MTHFR (methylenetetrahydrofolate reductase) 677 C>T and 1298 A>C polymorphisms in BCR–ABL-negative myeloproliferative neoplasms. *Int jnl hem lab.* doi: 10.1111/ijlh.12017
4. Sumitaka Yamanaka, Alexandru V Olaru, Delgermaa Luvsanjav, Fangmei An, Zhe Jin, Rachana Agarwal, Ciprian Tomuleasa, Irinel Popescu, Sorin Alexandrescu, **Delia Dima**, Mihaela Chivu-Economescu, Elizabeth Montgomery, Michael Torbenson, Christine Vazquez, Stephen J Meltzer, Florin M Selaru. MICRORNA-21 INHIBITS SERPINI 1, A GENE WITH NOVEL TUMOR SUPPRESSIVE EFFECTS IN GASTRIC CANCER. *Digestive and Liver Diseases*, 2012, 44(7) 589-596. **IF: 3.05**
5. Bănescu C, Iancu M, Trifa AP, Macarie I, **Dima D**, Dobreanu M. The *MTHFR* (methylenetetrahydrofolate reductase) 677 C>T polymorphism increases the risk of developing chronic myeloid leukemia. *IJHL*. 10-13- 0317. **IF 3.611**
6. **Delia Dima**, Ciprian Tomuleasa, Alexandru Irimie, Ioan Stefan Florian, Bobe Petrushev, Ioana Berindan- Neagoe, Andrei Cucuianu. Magnetic resonance imaging-based diagnosis of Progressive multifocal leukoencephalopathy in a patient with non-Hodgkin's lymphoma following therapy with cyclophosphamide, hydroxydaunorubicine, vincristine, prednison and rituximab. *Cancer*. 2014;120(24):4005-6. **IF: 5.2**
7. **Delia Dima**, Ciprian Tomuleasa, Rares Buiga, Bobe Petrushev, Ioana Frinc, Ioana Berindan-Neagoe, Andrei Cucuianu. Non-HIV- associated tonsillar Kaposiform hemangioendothelioma in a patient with Angioimmunoblastic lymphoma following therapy with cyclophosphamide, vincristine and prednison (COP). *Annales de Pathologie* 2014, in press. **IF: 0.2**
9. Ciprian Tomuleasa, **Delia Dima**, Ioana Frinc, Mariana Patiu, Bobe Petrushev, Andrei Cucuianu, Ioana Berindan-Neagoe. BCR-ABL T315I mutation, a negative pronostic factor for the terminal phase of Chronic Myelogenous Leukemia treated with first and second line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplantation as the treatment of choice. *Leukemia and Lymphoma* 2015, in press. **IF:2.301**
10. Andrei Cucuianu, Mariana Patiu, Adrian P. Trifa, Ciprian Tomuleasa, **Delia Dima**. Redistribution of iron towards deposits in erythblastopenic anemia as a consequence of decreased erythroferrone production. *Medical Hypotheses* 2014, in press. **IF: 1.054**
11. Ciprian Tomuleasa, Shigeo Fuji, Andrei Cucuianu, Markus Kapp, Sonia Selicean, Alina Tanase, **Delia Dima**, Bobe Petrushev, Valentina Pileczki, Ioana Berindan-Neagoe, Alexandru Irimie, Hermann Einsele. MICRORNAS for the diagnosis of Graft versus host disease. *Annals of Hematology* 2014, accepted for publication. **IF: 2.866**
12. Bănescu C, Trifa AP, Voidăzan S, Moldovan VG, Macarie I, Benedek Lazar E, **Dima D**, Duicu C, Dobreanu M. CAT, GPX1, MnSOD, GSTM1, GSTT1, and GSTP1 genetic polymorphisms in

chronic myeloid leukemia: a case-control study. *Oxid Med Cell Longev*. 2014; 2014:875861. ISI 3.516. **IF 1.281**

13. Bănescu C, Trifa AP, Demian S, Benedek Lazar E, **Dima D**, Duicu C, Dobreanu M. Polymorphism of XRCC1, XRCC3, and XPD genes and risk of chronic myeloid leukemia. *Biomed Res Int*. 2014;2014:213790. ISI 1.579
14. Ravnit Grewal, Andrei Cucuianu, Carmen Swanepoel, **Delia Dima**, Bobe Petrushev, Bogdan Pop, Ioana Berindan-Neagoe, Emmanuel Akin Abayomi, Ciprian Tomuleasa. The role of MICRORNAS in the pathogenesis of HIV-related lymphomas. *Critical Reviews in Clinical Laboratory Sciences* 2015, accepted for publication. **IF: 7.00**
15. **Delia Dima**, Cristian Tefas, Miruna Grecea, Ioana Frinc, Ciprian Tomuleasa, Andrei Cucuianu. Portal hypertension in previously treated, non-relapse related Hodgkin's lymphoma. *Clinical Leukemia Lymphoma and Myeloma* 2015, submitted for publication. **IF: 1.075**
16. Ciprian Tomuleasa, Bobe Petrushev, Madalina Vedean, Alexandru Irimie, Florin Zaharie, Ana Maria Rosu, **Delia Dima**, Andrei Cucuianu, Ioana Frinc. Bicytopenia as a paraneoplastic syndrome for pseudomyxoma peritonei. Hematologic manifestations of a subtle disease. *International Journal of General Medicine* 2014, in press
17. Andrei Cucuianu, Bobe Petrushev, Doinita Crisan, Rares Buiga, Ana Maria Rosu, **Delia Dima**, Ciprian Tomuleasa. Chronic granulomatous dermatosis as a presenting sign for cutaneous T-cell lymphomas. *European Journal of Dermatology* 2014, accepted for publication. **IF: 1.92**
18. Liren Qian, **Delia Dima**, Alina Tanase, Jian Cen, Cristian Berce, Lajos Raduly, Valentina Pileczki, Anca Buzoianu, Ioana Berindan-Neagoe, Alexandru Irimie, Jianliang Shen, Ciprian Tomuleasa. Exosomes as carriers of protein-based biomarkers of Graft-versus-Host disease in allogeneic stem cell transplantation for hematologic malignancies. *Critical Reviews in Clinical Laboratory Sciences* 2015, submitted for publication. **IF: 7.00**
19. Fetica B, Achimas-Cadariu PA, Pop B, **Dima D**, Petrov L, Perry AM, Nathwani BN, Muller-Hermelink HK, Diebold J, MacLennan KA, Fulop A, Blaga ML, Coza D, Nicula FA, Irimie A, Weisburger DD. Non-Hodgkin Lymphoma In Romania: A Single-Centre Experience. *Hematol Oncol* 2015; 2:10
20. Zaharie F, Cojocneanu-Petric R, Muresan M, Frinc I, **Dima D**, Petrushev B, Tanase A, Berce C, Chitic M, Berindan-Neagoe I, Pileczki V, Irimie A, Tomuleasa C. Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation. *International journal of nanomedicine* 2015;10; 1-3
21. Tomuleasa C, Akin-Abayomi E, **Dima D**, Tefas C, Irimie A, Petrushev B, Frinc I, Grewal R. Do lymphomas have an autoimmune background and how can we increase the sensitivity of the diagnosis of primary pancreatic lymphoma with relatively small samples ? *J Gastrointest Liver Dis*. 2015 Sep;24(3):391-2
22. Muresan M, Zaharie F, Bojan A, Frinc I, **Dima D**, Selicean S, Gafencu GA, Petrushev B, Cojocneanu-Petric R, Tefas C, Cioca A, Irimie A, Berce C, Berindan-Neagoe I, Tomuleasa C,

Achimas-Cadariu P. MicroRNAs in liver malignancies. Basic science applied in surgery. J BUON. 2015 Mar-Apr;20(2):361-75. Review

23. Grigore-Aristide Gafencu, Sonia Selicean, Bobe Petrushev, Andrei Cucuianu, **Delia Dima**, Ioana Frinc, Alexandru Irimie, Rares Buiga, Valentina Pileczki, Ioana Berindan-Neagoe, Cristian Berce, Ciprian Tomuleasa. CLINICOPATHOLOGICAL ANALYSIS OF A CASE SERIES OF PERIPHERAL T-CELL LYMPHOMAS, NOT OTHERWISE SPECIFIED, OF LYMPHOEPITELIOID VARIANT (LENNER'S LYMPHOMA). A CENTRAL EUROPEAN SINGLE-CENTER STUDY. Human Pathology, accepted for publication. **IF: 2.769**
24. Anca Bojan, Ioana Berindan-Neagoe, Stefan Ciurea, **Delia Dima**, Shigeo Fuji, Gabriel Ghiaur, Ravnit Grewal, Emmet McCormack, Alina Tanase, Adrian Trifa, Ciprian Tomuleasa. PROCEEDINGS FROM THE 1ST INSIGHTS IN HEMATOLOGY SYMPOSIUM, CLUJ NAPOCA, ROMANIA MARCH 11-12, 2016. Romanian Journal of Internal Medicine 2016; 54(3):157-160
25. Adrian P. Trifa, Claudia Banescu, Mihaela Tevet, Anca Bojan, Delia Dima, Laura Urian, Tunde Torok-Vistai, Viola M.Popov, Mhnea Zdrengea, Ljubomir Petrov, AncaVasilache, Meilin Murat, Daniela Georgescu, Mihaela Popescu, Oana Patrinoiu, Marius Balea, Roxana Costache, Elena Coles, Carmen Saguna, Nicoleta Berbec, Ana-Maria Vladareanu, Romeo G. Mihaila, Horia Bumbea, Andrei Cucuianu, Radu A. Popp. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms – a multicentric study on 529 patients. British Journal of Haematology, 2016, 174, 218–226
26. **Delia Dima**, Ciprian Tomuleasa, Ioana Frinc, Sergiu Pasca, Lorand Magdo, Mihai Muresan, Ioana Berindan-Neagoe, Cosmin Lisencu, Alexandru Irimie, Mihnea Zdrengea. THE USE OF ROTATION TO FENTANYL IN CANCER-RELATED PAIN. Journal of Pain Research, 2017; 10:341-348. IF: 2.363
27. **Delia Dima**, Ciprian Tomuleasa, Mihnea Zdrengea. HENOCHE SCHONLEIN PURPURA AND CLOSTRIDIUM DIFFICILE INFECTION, A HEMATOLOGISTS' POINT OF VIEW. Journal of Gastrointestinal and Liver Diseases, submitted for publication. **IF: 2.202**
28. Bobe Petrushev, Sanda Boca, Timea Simon, Cristian Berce, Ioana Frinc, **Delia Dima**, Sonia Selicean, Grigore-Aristide Gafencu, Alina Tanase, Mihnea Zdrengea, Adrian Florea, Sorina Suarasan, Liana Dima, Raluca Stanciu, Ancuta Jurj, Anca Buzoianu, Andrei Cucuianu, Simion Astilean, Alexandru Irimie, Ciprian Tomuleasa, Ioana Berindan-Neagoe. GOLD NANOPARTICLES ENHANCE THE EFFECT OF TYROSIN KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA THERAPY. International Journal of Nanomedicine 2016;11 641–660. IF: **4.383**
29. Sanda Boca, Ciprian Lucan, Ioana Frinc, Bobe Petrushev, Timea Simon, Cristian Berce, Grigore-Aristide Gafencu, **Delia Dima**, Alina Tanase, Sonia Selicean, Valentina Pileczki, Laura Pop, Adrian

Florea, Alexandru Irimie, Simion Astilean, Anca Bojan, Ioana Berindan-Neagoe, Mihnea Zdrengea, Ciprian Tomuleasa. GOLD NANOPARTICLES CONJUGATED WITH RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. Farmacia 2016, accepted for publication. IF: 1.162

30. Ioana Frinc, Petru Ilies, **Delia Dima**, Alina Tanase, Ljubomir Petrov, Alexandru Irimie, Bobe Petrushev, Cristian Berce, Mihai-Stefan Muresan, Cosmin Lisencu, Ioana Berindan-Neagoe, Anca Bojan, Ciprian Tomuleasa. TRANSTHORACIC ULTRASONOGRAPHY FOR THE IMMUNOCOMPROMISED PATIENT. Romanian Journal of Internal Medicine, 2017 Jun 1;55(2):103-116
31. Ciprian Tomuleasa, Sonia Selicean, Grigore Gafencu, Bobe Petrushev, Laura Pop, Cristian Berce, Anca Jurj, Adrian Trifa, Ana-Maria Rosu, Sergiu Pasca, Lorand Magdo, Mihnea Zdrengea, **Delia Dima**, Alina Tanase, Ioana Frinc, Anca Bojan, Ioana Berindan-Neagoe, Gabriel Ghiaur, Stefan O. Ciurea. Fibroblast Dynamics as an *In Vitro* Screening Platform for Anti-fibrotic Drugs in Primary Myelofibrosis. J Cell Physiol. 2017, doi: 10.1002/jcp.25902. IF: 4.155
32. **Delia Dima**, Liana Oprita, Ana-Maria Rosu, Bobe Petrushev, Adrian Trifa, Cristina Selicean, Vlad Moisoiu, Ioana Rus, Mihnea Zdrengea, Ciprian Tomuleasa. ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA. RARE ASSOCIATION WITH CYTOPENIAS OF UNDETERMINED SIGNIFICANCE AND P210 AND P190 *BCR-ABL* TRANSCRIPTS. OncoTargets and Therapy, 2017; 10:5047-5051. IF: 2.311
33. Ioana Frinc, **Delia Dima**, Mariana Chitic, Cristian Berce, Ioana Berindan-Neagoe, Tiberiu Tat, Alina Tanase, Ciprian Tomuleasa, Anca Bojan. TRANSTHORACIC ULTRASONOGRAPHY FOR THE FOLLOW-UP OF A CHRONIC LYMPHOCYTIC LEUKEMIA CHEMOTHERAPY-IMMUNOCOMPROMISED PATIENT PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION. CASE REPORT. Medical Ultrasonography, 2017 Mar 14;19(3):330-332.. IF 1.167
34. Adrian Trifa, Claudia Banescu, Anca Bojan, Alina Popa, Florin Tripon, **Delia Dima**, Viola Maria Popov, Stefan Vesa, Mihaela Andreescu, Tunde Torok-Vistai, Romeo Mihaila, Nicoleta Berbec, Ion Macarie, Andrei Colita, Maria Iordache, Alina Catana, Marius Farcas, Ciprian Tomuleasa, Kinga Vasile, Cristina Truica, Adriana Todinca, Lavinia Muntean, Raluca Manolache, Horia Bumbea, Ana-Maria Vladareanu, Mihaela Dervesteanu, Cristina Ciufu, Radu Popp. MECOM, HBS1L-MYB, THRB-RARB, JAK2 and TERT polymorphisms defining predisposition to myeloproliferative neoplasms - a study on 939 patients. American Journal of Hematology, 2017, doi: 10.1002/ajh.24946. IF: 5.275
35. Ciprian Tomuleasa, Mihai Stefan Muresan, Florin Zaharie, Laura Pop, Zsolt Fekete, **Delia Dima**, Ioana Frinc, Adrian Trifa, Cristian Berce, Ancuta Jurj, Ioana Berindan-Neagoe, Mihnea Zdrengea, Tudor Ciuleanu. HOW TO DIAGNOSE AND TREAT A CANCER OF UNKNOWN PRIMARY SITE. Journal of Gastrointestinal and Liver Diseases, 2017; 26(1):69-79. IF: 2.202

36. Qian L, **Dima D**, Berce C, Liu Y, Rus I, Raduly LZ, Liu Y, Petrushev B, Berindan-Neagoe I, Irimie A, Tanase A, Jurj A, Shen J, Tomuleasa C. Protein dysregulation in graft versus host disease. *Oncotarget*. 2017 Dec 15;9(1):1483-1491. doi: 10.18632/oncotarget.23276
37. Qian L, Tomuleasa C, Florian IA, Shen J, Florian IS, Zdrenghia M, Dima D. Advances in the treatment of newly diagnosed primary central nervous system lymphomas. *Blood Res*. 2017 Sep;52(3):159-166. doi: 10.5045/br.2017.52.3.15
38. Trifa AP, Bănescu C, Voina CM, Popa Ș, Török-Vistai T, Bojan AS, **Dima D**, Zdrenghia M, Fetica B, Vișan S, Tomuleasa C, Pârva A, Urian L, Pop B, Popov VM, Andreescu M, Popp RA. Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycythemia vera and essential thrombocythemia. *Blood Cells Mol Dis*. 2018 Nov;73:45-46. doi: 10.1016/j.bcmd.2018.09.003
39. Jurj A, Pop L, Petrushev B, Pasca S, **Dima D**, Frinc I, Deak D, Desmirean M, Trifa A, Fetica B, Gafencu G, Selicean S, Moisoiu V, Micu WT, Berce C, Sacu A, Moldovan A, Colita A, Bumbea H, Tanase A, Dascalescu A, Zdrenghia M, Stiuftuc R, Leopold N, Tetean R, Burzo E, Tomuleasa C, Berindan-Neagoe I. Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome. *Crit Rev Clin Lab Sci*. 2018 Nov;55(7):501-515. doi: 10.1080/10408363.2018.1499707
40. Lazar MA, Muresan O, Roman CR, **Dima D**, Muresan MS, Armencea G, Tomuleasa C, Rotaru H. Oral surgery for combined haemophilia A and B. The dos and don'ts presented in a clinical scenario. *Ann Ital Chir*. 2018;89:374-378
41. Mester A, Irimie A, Oprita L, **Dima D**, Petrushev B, Lucaciu O, Campian RS, Tanase A. Oral manifestations in stem cell transplantation for acute myeloid leukemia. *Med Hypotheses*. 2018 Dec;121:191-194. doi: 10.1016/j.mehy.2018.06.015
42. Zaharie F, Muresan MS, Tomuleasa C, Popa G, Blag C, Zaharie R, Zdrehus C, Dragomir M, Bumbea H, Irimie A, **Dima D**. Laparoscopic splenectomy for hereditary spherocytosis. A case series and review of the literature. *Ann Ital Chir*. 2018 Jul 11;7. pii: S0003469X18028701
43. Tat T, Li H, Constantinescu CS, Onaciu A, Chira S, Osan C, Pasca S, Petrushev B, Moisoiu V, Micu WT, Berce C, Tranca S, **Dima D**, Berindan-Neagoe I, Shen J, Tomuleasa C, Qian L. Genetically enhanced T lymphocytes and the intensive care unit. *Oncotarget*. 2018 Aug 10;9(62):32097. doi: 10.18632/oncotarget.25983
44. Traila A, **Dima D**, Achimas-Cadariu P, Micu R. Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era. *Cancer Manag Res*. 2018 Jun 13;10:1517-1526. doi: 10.2147/CMAR.S154819
45. Tomuleasa C, Selicean C, Cismas S, Jurj A, Marian M, **Dima D**, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghia M, Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-Neagoe I. Minimal residual disease in chronic lymphocytic leukemia: A

consensus paper that presents the clinical impact of the presently available laboratory approaches. Crit Rev Clin Lab Sci. 2018 Aug;55(5):329-345. doi: 10.1080/10408363.2018.1463508

46. Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, **Dima D**, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA *CCAT2* induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 Apr;28(4):432-447. doi: 10.1101/gr.225128.117
47. Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, **Dima D**, Kitano S. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239
48. Catalin Constantinescu, Constantin Bodolea, Sergiu Pasca, Patric Teodorescu, **Delia Dima**, Ioana Rus, Tiberiu Tat, Daniela Ionescu, Mihnea Zdrengea, Patriciu Achimas-Cadariu, Alina Tanase, Ciprian Tomuleasa· Hermann Einsele. · Clinical approach to the patient in critical state following immunotherapy and/or stem cell transplantation. Guideline for the on-call physician. J lin Med, 2019, 8, 884; doi:10.3390. IF: 5.688
49. Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, Craciun OG, Soare D, Ghimici C, Manolache R, Gelatu I, Vladareanu AM, Pasca S, Teodorescu P, **Dima D**, Lupu A, Coriu D, Tomuleasa C, Tanase A. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol. 2019 Sep 10;9:892. doi: 10.3389/fonc.2019.00892. eCollection 2019.
50. Claudia Bănescu, Florin Tripon, Adrian P. Trifa, Andrei G Crauciuc, Valeriu G. Moldovan, Alina Bogliș, Istvan Benedek, **Delia Dima**, Marcela Căndea, Carmen Duicu, Mihaela Iancu. Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia. Cancer Medicine 2019;8:5492–5506
51. Jerome Dobrowolski, Segiu Pasca, Patric Teodorescu, Cristina Selicean, Ioana Rus Mihnea Zdrengea, Anca Bojan, Adrian Trifa, Bogdan Fetica, Bobe Petrushev, Ana-Maria Rosu, Ioana Berindan-Neagoe, Ciprian Tomuleasa, **Delia Dima**. Persistent basophilia may suggest an „accelerated phase” in the evolution of CALR-positive primary myelofibrosis toward acute myeloid leukemia. Frontiers in Oncology 2019; 8, 8721 doi:10.3389

52. Sas V, Blag C, Zaharie G, Puscas E, Lisencu C, Andronic-Gorcea N, Pasca S, Petrushev B, Chis I, Marian M, **Dima D**, Teodorescu P, Iluta S, Zdrenghia M, Berindan-Neagoe I, Popa G, Man S, Colita A, Stefan C, Kojima S, Tomuleasa C. Transient leukemia of Down syndrome. *Crit Rev Clin Lab Sci*. 2019 Jun; 56 (4):247-259. doi: 10.1080/10408363.2019.161362
53. Zaharie F, Pop LA, Petrushev B, Jurj A, Muresan MS, Eniu D, Fetica B, Petkov B, Pasca S, Piciu D, Rus I, Deak D, **Dima D**, Desmirean MS, Tomuleasa C, Berindan-Neagoe I. Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient. *Histol Histopathol*. 2019 Jun;34(6):663-670. doi: 10.14670/HH-18-067
54. Moisoiu V, Teodorescu P, Parajdi L, Pasca S, Zdrenghia M, **Dima D**, Precup R, Tomuleasa C, Soverini S. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the *Avant-Garde* of Molecular Hematology. *Front Oncol*. 2019 Sep 23;9:863. doi: 10.3389/fonc.2019.00863. eCollection 2019.
55. Pasca S, Tomuleasa C, Teodorescu P, Ghiaur G, **Dima D**, Moisoiu V, Berce C, Stefan C, Ciechanover A, Einsele H. KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma. *Front Oncol*. 2019 Oct 24;9:1137. doi: 10.3389/fonc.2019.01137. eCollection 2019.
56. Moisoiu V, Stefancu A, Iancu SD, Moisoiu T, Loga L, Dican L, Alecsa CD, Boros I, Jurj A, **Dima D**, Bagacean C, Teteian R, Burzo E, Tomuleasa C, Elec F, Leopold N. SERS assessment of the cancer-specific methylation pattern of genomic DNA: towards the detection of acute myeloid leukemia in patients undergoing hematopoietic stem cell transplantation. *Anal Bioanal Chem*. 2019 Nov; 411(29):7907-7913. doi: 10.1007/s00216-019-02213-2. Epub 2019 Nov 20.
57. Desmirean M, Deak D, Rus I, **Dima D**, Iluta S, Preda A, Moldovan T, Roman A, Tomuleasa C, Petrushev B. Paraneoplastic hypereosinophilia in a patient with peripheral T cell lymphoma, not otherwise specified. *Med Pharm Rep*. 2019 Oct;92(4):421-426. doi: 10.15386/mpr-1347. Epub 2019 Oct 25.
58. Bănescu C, Tripon F, Trifa AP, Crauciuc AG, Bogliș A, Lazar E, **Dima D**, Macarie I, Duicu C, Iancu M. Presence of copy number aberration and clinical prognostic factors in patients with acute myeloid leukemia: an analysis of effect modification. *Pol Arch Intern Med*. 2019 Dec 23;129(12):898-906. doi: 10.20452/pamw.15093. Epub 2019 Dec 6.
59. Deak D, Pop C, Zimta AA, Jurj A, Ghiaur A, Pasca S, Teodorescu P, Dascalescu A, Antohe I, Ionescu B, Constantinescu C, Onaciu A, Munteanu R, Berindan-Neagoe I, Petrushev B, Turcas C, Iluta S, Selicean C, Zdrenghia M, Tanase A, Danaila C, Colita A, Colita A, **Dima D**, Coriu D, Einsele H, Tomuleasa C. Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. *Front Immunol*. 2019 Dec 20;10:2856. doi: 10.3389/fimmu.2019.02856. eCollection 2019.

60. Tripon F, Iancu M, Trifa A, Crauciuc GA, Boglis A, **Dima D**, Lazar E, Bănescu C. Modelling the Effects of MCM7 Variants, Somatic Mutations, and Clinical Features on Acute Myeloid Leukemia Susceptibility and Prognosis. *J Clin Med*. 2020 Jan 8;9(1):158. doi: 10.3390/jcm9010158.
61. Mester A, Irimie AI, Tanase A, Tranca S, Campian RS, Tomuleasa C, **Dima D**, Piciu A, Lucaciu O. Periodontal disease might be a risk factor for graft versus host disease. A systematic review. *Crit Rev Oncol Hematol*. 2020 Mar;147:102878. doi: 10.1016/j.critrevonc.2020.102878. Epub 2020 Jan 23.
62. Pasca S, Turcas C, Jurj A, Teodorescu P, Iluta S, Hotea I, Bojan A, Selicean C, Fetica B, Petrushev B, Moisoiu V, Zimta AA, Sas V, Constantinescu C, Zdrenghea M, **Dima D**, Tomuleasa C. The Influence of Methylating Mutations on Acute Myeloid Leukemia: Preliminary Analysis on 56 Patients. *Diagnostics (Basel)*. 2020 Apr 29;10(5):263. doi: 10.3390/diagnostics10050263.
63. Bănescu C, Tripon F, Trifa AP, Crauciuc AG, Bogliș A, Lazar E, **Dima D**, Macarie I, Duicu C, Iancu M. Presence of copy number aberrations and clinical prognostic factors in patients with acute myeloid leukemia: an analysis of effect modification. Authors' reply. *Pol Arch Intern Med*. 2020 Apr 30;130(4):347-348. doi: 10.20452/pamw.15327. Epub 2020 Apr 30.
64. Constantinescu C, Pasca S, Tat T, Teodorescu P, Vlad C, Iluta S, **Dima D**, Tomescu D, Scarlatescu E, Tanase A, Sigurjonsson OE, Colita A, Einsele H, Tomuleasa C. Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies? *J Immunother Cancer*. 2020 May;8(1):e000742. doi: 10.1136/jitc-2020-000742.
65. Tripon F, Iancu M, Trifa A, Crauciuc GA, Boglis A, Balla B, Cosma A, **Dima D**, Candea M, Lazar E, Jimbu L, Banescu C. Association Analysis of TP53 rs1042522, MDM2 rs2279744, rs3730485, MDM4 rs4245739 Variants and Acute Myeloid Leukemia Susceptibility, Risk Stratification Scores, and Clinical Features: An Exploratory Study. *J Clin Med*. 2020 Jun 1;9(6):1672. doi: 10.3390/jcm9061672.
66. Turcas C, Moisoiu V, Stefancu A, Jurj A, Iancu SD, Teodorescu P, Pasca S, Bojan A, Trifa A, Iluta S, Zimta AA, Petrushev B, Zdrenghea M, Bumbea H, Coriu D, **Dima D**, Leopold N, Tomuleasa C. SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia? *Front Oncol*. 2020 Jun 29;10:1024. doi: 10.3389/fonc.2020.01024. eCollection 2020.
67. Teodorescu P, Pasca S, **Dima D**, Tomuleasa C, Ghiaur G. Targeting the Microenvironment in MDS: The Final Frontier. *Front Pharmacol*. 2020 Jul 9;11:1044. doi: 10.3389/fphar.2020.01044. eCollection 2020.
68. Tomuleasa C, Iluta S, Pasca S, Roman A, Piciu D, Jitaru C, Teodorescu P, Rus I, Bojan A, **Dima D**, Zdrenghea M, Petrushev B. Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab. *Int J Hematol*. 2020 Oct;112(4):597-598. doi: 10.1007/s12185-020-02989-5. Epub 2020 Sep 4.
69. Teodorescu P, Pasca S, Jurj A, Gafencu G, Joelsson JP, Selicean S, Moldovan C, Munteanu R, Onaciu A, Tigu AB, Buse M, Zimta AA, Stiufiuc R, Petrushev B, Desmirean M, **Dima D**, Vlad C,

- Bergthorsson JT, Berce C, Ciurea S, Ghiaur G, Tomuleasa C. Transforming growth factor β -mediated micromechanics modulates disease progression in primary myelofibrosis. *J Cell Mol Med*. 2020 Oct;24(19):11100-11110. doi: 10.1111/jcmm.15526. Epub 2020 Sep 5.
70. Sas V, Pasca S, Jurj A, Pop L, Muramatsu H, Ono H, **Dima D**, Teodorescu P, Iluta S, Turcas C, Onaciu A, Munteanu R, Zimta AA, Blag C, Popa G, von Gamm EDA, Arghirescu S, Serban M, Man S, Marian M, Petrushev B, Berce C, Colita A, Zdrenghia M, Kojima S, Gulei D, Takahashi Y, Tomuleasa C. MicroRNA-155-5p Plays a Critical Role in Transient Leukemia of Down Syndrome by Targeting Tumor Necrosis Factor Receptor Superfamily Members. *Cell Physiol Biochem*. 2020 Oct 3;54(5):994-1012. doi: 10.33594/000000283.
 71. Desmirean M, Rauch S, Jurj A, Pasca S, Iluta S, Teodorescu P, Berce C, Zimta AA, Turcas C, Tigu AB, Moldovan C, Paris I, Steinheber J, Richlitzki C, Constantinescu C, Sigurjonsson OE, **Dima D**, Petrushev B, Tomuleasa C. B Cells versus T Cells in the Tumor Microenvironment of Malignant Lymphomas. Are the Lymphocytes Playing the Roles of Muhammad Ali versus George Foreman in Zaire 1974? *J Clin Med*. 2020 Oct 24;9(11):3412. doi: 10.3390/jcm9113412.
 72. Lighezan DL, Bojan AS, Iancu M, Pop RM, Gligor-Popa Ș, Tripon F, Cosma AS, Tomuleasa C, **Dima D**, Zdrenghia M, Fetica B, Ioniță I, Gaál IO, Vișan S, Mirea AM, Popp RA, Florea M, Araniciu C, Petrescu L, Pop IV, Bănescu C, Trifa AP. *TET2* rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis. *J Pers Med*. 2020 Dec 1;10(4):259. doi: 10.3390/jpm10040259.
 73. Sas V, Blag C, Pasca S, Popa G, Marian M, Schnell C, Voda D, Arghirescu ST, Teodorescu P, Iluta S, Turcas C, Selicean C, Bojan A, Zdrenghia M, Serban M, **Dima D**, Zaharie G, Colita A, Man S, Tomuleasa C. Baseline characteristics of a nationwide cohort of pediatric patients with acute leukemias of Down syndrome. *J BUON*. 2020 Nov-Dec;25(6):2737-2746.
 74. Iluta S, Pasca S, **Dima D**, Mester G, Urian L, Bojan A, Zdrenghia M, Trifa A, Balacescu O, Tomuleasa C. Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease. *Eur J Hosp Pharm*. 2022 Nov;29(6):e8. doi: 10.1136/ejhpharm-2021-002694. Epub 2021 Feb 4.
 75. Deak D, Gorcea-Andronic N, Sas V, Teodorescu P, Constantinescu C, Iluta S, Pasca S, Hotea I, Turcas C, Moisoiu V, Zimta AA, Galdean S, Steinheber J, Rus I, Rauch S, Richlitzki C, Munteanu R, Jurj A, Petrushev B, Selicean C, Marian M, Soritau O, Andries A, Roman A, **Dima D**, Tanase A, Sigurjonsson O, Tomuleasa C. A narrative review of central nervous system involvement in acute leukemias. *Ann Transl Med*. 2021 Jan;9(1):68. doi: 10.21037/atm-20-3140.
 76. Jimbu L, Mesaros O, Popescu C, Neaga A, Berceanu I, **Dima D**, Gaman M, Zdrenghia M. Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia? *Pharmaceuticals (Basel)*. 2021 Mar 24;14(4):288. doi: 10.3390/ph14040288.
 77. Zimta AA, Hotea I, Brinza M, Blag C, Iluta S, Constantinescu C, Bashimov A, Marchis-Hund EA, Coudsy A, Muller-Mohnssen L, Dirzu N, Gulei D, **Dima D**, Serban M, Coriu D, Tomuleasa C. The

Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A. *Front Med (Lausanne)*. 2021 Apr 15;8:654197. doi: 10.3389/fmed.2021.654197. eCollection 2021.

78. Iluta S, Pasca S, Gafencu G, Jurj A, Terec A, Teodorescu P, Selicean C, Jitaru C, Preda A, Cenariu D, Constantinescu C, Iordache M, Tigiu B, Munteanu R, Feder R, **Dima D**, Zdrengeha M, Gulei D, Ciuleanu TE, Tomuleasa C. Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy. *J Cell Mol Med*. 2021 Jul;25(13):6094-6102. doi: 10.1111/jcmm.16513. Epub 2021 Jun 16
79. Stefancu A, Moisoiu V, Desmirean M, Iancu SD, Tigiu AB, Petrushev B, Jurj A, Cozan RG, Budisan L, Fetica B, Roman A, Dobie G, Turcas C, Zdrengeha M, Teodorescu P, Pasca S, Piciu D, **Dima D**, Bálint Z, Leopold N, Tomuleasa C. SERS-based DNA methylation profiling allows the differential diagnosis of malignant lymphadenopathy. *Spectrochim Acta A Mol Biomol Spectrosc*. 2022 Jan 5;264:120216. doi: 10.1016/j.saa.2021.120216. Epub 2021 Jul 21.
80. Moisoiu V, Sas V, Stefancu A, Iancu SD, Jurj A, Pasca S, Iluta S, Zimta AA, Tigiu AB, Teodorescu P, Turcas C, Blag C, **Dima D**, Popa G, Arghirescu S, Man S, Colita A, Leopold N, Tomuleasa C. SERS-Based Evaluation of the DNA Methylation Pattern Associated With Progression in Clonal Leukemogenesis of Down Syndrome. *Front Bioeng Biotechnol*. 2021 Jul 23;9:703268. doi: 10.3389/fbioe.2021.703268. eCollection 2021.
81. Hotea I, Brinza M, Blag C, Zimta AA, Dirzu N, Burzo C, Rus I, Apostu D, Benea H, Marian M, Mester A, Pasca S, Iluta S, Teodorescu P, Jitaru C, Zdrengeha M, Bojan A, Torok-Vistai T, Niculescu R, Tarniceriu C, **Dima D**, Truica C, Serban M, Tomuleasa C, Coriu D. Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology. *Ann Transl Med*. 2021 Jul;9(13):1091. doi: 10.21037/atm-21-747.
82. Desmirean M, Richlitzki C, Pasca S, Teodorescu P, Petrushev B, Rauch S, Steinheber J, Iluta S, Liu J, **Dima D**, Grewal R, Ma W, Qian L, Tomuleasa C. Correlation between the prevalence of T-cell lymphomas and alcohol consumption. *Med Pharm Rep*. 2021 Jul;94(3):298-306. doi: 10.15386/mpr-1777. Epub 2021 Jul 29.
83. Dirzu N, Hotea I, Jitaru C, Brinza M, Urian L, Peters MC, Gal K, Popescu L, Blag C, Marian M, Pal E, Stanescu M, Cenariu D, Tarniceriu C, Serban M, **Dima D**, Coriu D, Tomuleasa C. Mobile Health Technology for the Personalized Therapy of Hemophilia. *Front Med (Lausanne)*. 2021 Aug 10;8:711973. doi: 10.3389/fmed.2021.711973. eCollection 2021.
84. Deak-Mihaly D, Iluta S, Pasca S, Jitaru C, Roman A, Andries A, Padurariu-Covit M, Petrushev B, Vasilache A, Bojan A, Zdrengeha M, Dascalescu A, Antohe I, Colita A, Colita A, **Dima D**, Tanase A, Tomuleasa C. Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma. *J Clin Med*. 2021 Sep 29;10(19):4483. doi: 10.3390/jcm10194483.
85. Constantinescu C, Pasca S, Iluta S, Gafencu G, Santa M, Jitaru C, Teodorescu P, **Dima D**, Zdrengeha M, Tomuleasa C. The Predictive Role of Modified Early Warning Score in 174

Hematological Patients at the Point of Transfer to the Intensive Care Unit. *J Clin Med*. 2021 Oct 18;10(20):4766. doi: 10.3390/jcm10204766.

86. Constantinescu C, Jitaru C, Pasca S, **Dima D**, Dirzu N, Coriu D, Zdziarska J, Ghiaur G, Mahlangu J, Tomuleasa C. Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B. *Blood Rev*. 2022 May;53:100907. doi: 10.1016/j.blre.2021.100907. Epub 2021 Nov 10.
87. Jimbu L, Mesaros O, Neaga A, Nanut AM, Tomuleasa C, **Dima D**, Bocsan C, Zdrengeha M. The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia. *Pharmaceuticals (Basel)*. 2021 Oct 29;14(11):1105. doi: 10.3390/ph14111105.
88. Drula R, Iluta S, Gulei D, Iuga C, **Dima D**, Ghiaur G, Buzoianu AD, Ciechanover A, Tomuleasa C. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. *Blood Rev*. 2022 Nov;56:100971. doi: 10.1016/j.blre.2022.100971. Epub 2022 May 16.
89. Constantinescu C, Petrushev B, Rus I, Stefanescu H, Frasinariu O, Margarit S, **Dima D**, Tomuleasa C. Mechanistic Insights in Hemophagocytic Lymphohistiocytosis: Subsequent Acute Hepatic Failure in a Multiple Myeloma Patient Following Therapy with Ixazomib-Lenalidomide-Dexamethasone. *J Pers Med*. 2022 Apr 23;12(5):678. doi: 10.3390/jpm12050678.
90. Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B, Gulei D, **Dima D**, Tanase A, Einsele H, Ciurea S, Tomuleasa C, Caers J. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? *J Hematol Oncol*. 2022 Jun 7;15(1):78. doi: 10.1186/s13045-022-01296-2.
91. Arbore DR, Galdean SM, **Dima D**, Rus I, Kegyes D, Ababei RG, Dragancea D, Tomai RA, Trifa AP, Tomuleasa C. COVID-19 Impact on Chronic Myeloid Leukemia Patients. *J Pers Med*. 2022 Nov 10;12(11):1886. doi: 10.3390/jpm12111886.
92. Kegyes D, Gulei D, Drula R, Cenariu D, Tigu B, **Dima D**, Tanase A, Badelita S, Buzoianu AD, Ciurea S, Ghiaur G, Terpos E, Ciechanover A, Einsele H, Tomuleasa C. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. *Blood Rev*. 2023 Sep;61:101100. doi: 10.1016/j.blre.2023.101100. Epub 2023 May 27.
93. Cenariu D, Rus I, Bergthorsson JT, Grewal R, Cenariu M, Greiff V, Tigu AB, **Dima D**, Selicean C, Petrushev B, Zdrengeha M, Fromm J, Aanei CM, Tomuleasa C. Flow Cytometry of CD5-Positive Hairy Cell Leukemia. *Mol Diagn Ther*. 2023 Sep;27(5):593-599. doi: 10.1007/s40291-023-00658-x. Epub 2023 Jun 9.
94. Tigu AB, Hotea I, Drula R, Zimta AA, Dirzu N, Santa M, Constantinescu C, **Dima D**, Bergthorsson JT, Greiff V, Gulei D, Coriu D, Serban M, Mahlangu J, Tomuleasa C. RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia. *J Cell Mol Med*. 2023 Jul;27(13):1790-1796. doi: 10.1111/jcmm.17741. Epub 2023 Jun 14.
95. Tigu AB, Constantinescu CS, Teodorescu P, Kegyes D, Munteanu R, Feder R, Peters M, Pralea I, Iuga C, Cenariu D, Marcu A, Tanase A, Colita A, Drula R, Bergthorsson JT, Greiff V, **Dima D**,

- Selicean C, Rus I, Zdrenghia M, Gulei D, Ghiaur G, Tomuleasa C. Design and preclinical testing of an anti-CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia. *J Cell Mol Med*. 2023 Oct;27(19):2864-2875. doi: 10.1111/jcmm.17810. Epub 2023 Sep 4.
96. Jimbu L, Valeanu M, Trifa AP, Mesaros O, Bojan A, **Dima D**, Parvu A, Rus IC, Tomuleasa C, Torok T, Urian L, Vasilache A, Zdrenghia M. A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience. *Cureus*. 2023 Aug 20;15(8):e43794. doi: 10.7759/cureus.43794. eCollection 2023 Aug.
 97. Tomai RA, Oancea A, Tomuleasa C, **Dima D**. Capillary Leak Syndrome Associated with Anaplastic T Cell Lymphoma and Transcutaneous Exudation: An Unusual Presentation. *Diagnostics (Basel)*. 2024 Aug 31;14(17):1924. doi: 10.3390/diagnostics14171924.
 98. Gulei D, Moisiu V, Kegyes D, Drula R, Iluta S, Tigiu AB, Nistor M, Jitaru C, Bancos A, Rotariu P, Popovici C, **Dima D**, Tomai R, Rus I, Constantinescu C, Munteanu R, Cenariu D, Sezerman U, Zdrenghia M, Cermak J, Einsele H, Ghiaur G, Tomuleasa C. RNA methylation sequencing shows different gene expression signatures for response to azacytidine therapy in high-grade myelodysplastic syndromes. *J Cell Mol Med*. 2024 Sep;28(18):e70078. doi: 10.1111/jcmm.70078.
 99. Tomai RA, Iluta S, Tigiu AB, Nistor M, Bancos A, Cenariu D, Jitaru C, Patcas S, **Dima D**, Kegyes D, Buruiana S, Zdrenghia M, Tanase AD, Tomuleasa C, Micu R. "Lazarus Response" When Feto-Maternal Microchimerism Kicks in: Spontaneous Remission in Refractory Primary Mediastinal B Cell Lymphoma Following Twin Pregnancy. *Diagnostics (Basel)*. 2024 Sep 20;14(18):2084. doi: 10.3390/diagnostics14182084.
 100. Iluta S, Nistor M, Buruiana S, **Dima D**. Wnt Signaling Pathway in Tumor Biology. *Genes (Basel)*. 2024 Dec 13;15(12):1597. doi: 10.3390/genes15121597.
 101. Jitaru C, Symeonidis A, Badelita S, Katodritou E, Colita A, Mpanti A, Bancos A, Tigiu B, Torariu P, Urian L, Rus I, **Dima D**, Bojan A, Damian M, Labropoulou V, Muresan MS, Fotiou D, Fetica B, Petrushev B, Dascalescu An, Dalampira D, Buruiana S, Constantinescu C, Zdrenghia M, Dimopoulos M A, Tomuleasa C, Terpos E. Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience. *J Hematol* 2024; 13 (5): 207-215.
 102. Tanase Timis, Sanda Buruiana, **Delia Dima**, Madalina Nistor, Ximena Maria Muresan, Diana Cenariu, Adrian-Bogdan Tigiu, Ciprian Tomuleasa. Advances in Cell and Immune Therapy for Melanoma. *Biomedicines* 2025, 13(1), 98; <https://doi.org/10.3390/biomedicines13010098>
 103. Cortes E Jorge..., **Delia Dima**, Franck E Nicolini. Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial. *The Lancet Hematology* 2025 Feb 7:S2352-3026(24)00354-5 doi: 10.1016/S2352-3026(24)00354-5.
 104. Visceral Leishmaniasis in a 25-Year-Old Female Kidney Transplant Recipient from a Non-Endemic Region: A Case Report from Romania. Alin Gabriel Mihu, Mariana Patiu, **Delia Monica Dima**, Daniela Adriana Oatis, Daniela Adriana Oatis. *Microorganisms* 2025, 13, 403.

105. Oana Mesaros, Laura Jimbu, Ioana Rus, Andrada Parvu, Ciprian Tomuleasa, **Delia Dima**, Tunde Torok, Laura Urian, Anca Vasilache, Anca Bojan, Mihnea Zdrenghea. Real world outcomes with Ibrutinib monotherapy in chronic lymphocytic leukemia: a single center experience. 2025 Jan;98(1):36-45. doi: 10.15386/mpr-2800. Epub 2025 Jan 31.
106. Mihnea Lucian Micu¹, Simion Florin Cira¹, Mihnea Zdrenghea¹, Anca Bojan¹, Andrada Parvu¹, Tunde Torok-Vistai¹, Anca Vasilache¹, Laura Urian¹, Bancos Anamaria¹, Laura Ioana Jimbu¹, Maria-Elena Santa¹, Diana Lighezan², Adrian Bogdan Tigu¹, Andrei Ivancuta¹, Adrian Trifa², Elena-Cristina Selicean¹, Delia Dima¹, Rus Ioana Codruța^{1*} and Ciprian Tomuleasa^{1*}. In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR. Front. Pharmacol., 06 November 2025, Sec. Translational Pharmacology Volume 16 - 2025 | <https://doi.org/10.3389/fphar.2025.1673056>
- 107.
- 108.
- 109.
- 110.